News
-
Offers
Carna’s Profiling Services Discount Campaign!
Carna’s Next-Gen Mobility Shift Assay (MSA) System supporting kinase drug discovery is now operational with scientific and budget friendly…
-
General
Mobility-Shift-Assay-Detektionssystem der nächsten Generation!
Wir haben tolle Neuigkeiten für Sie: MSA ist für Ihre Inhibitorforschung weiterhin zugänglich!
-
General
Biotinylierte Kinasen
Wir haben neue Produkte: biologisch biotinylierte humane Kinasen von Carna Biosciences.
-
Offers
New Cellular CDK Assay Panel Launched and Special Offers from Carna
We are pleased to launch a new CDK (cyclin-dependent kinases) Cell-based Assay Panel for kinase researchers who are focusing on the CDK family.
… -
General
Neue Website online!
Wir freuen uns sehr, den Start unserer neuen Website bekannt geben zu können!
Wir haben beschlossen, dass es an der Zeit für einen neuen Look ist,…
Carna Biosciences Newsletter
-
Newsletter
Cancer treatments using inhibitors of CDK, a cell cycle regulator
Carna Newsletter Vol.16
-
Newsletter
ALK drug resistant mutations: Challenges for the treatment of lung cancer
Carna Newsletter Vol.15
-
Technical Note
DGKα and DGKζ are key targets for cancer immunotherapy
Carna Newsletter Vol.14
-
Newsletter
The potential of PIKfyve inhibitor as a treatment of amyotrophic lateral sclerosis (ALS)
Carna Newsletter Vol.13
-
Newsletter
The importance of understanding the activity of compounds on RAF dimerization in BRAF inhibitor drug discovery
Carna Biosciences Newsletter Vol. 12
-
Newsletter
Kinase Inhibitors as Potential Therapeutic Agents for COVID-19
Carna Biosciences Newsletter Vol. 11
-
Technical Note
Evaluating Kinase Inhibitors in Binding Assays using Activated and Non-Activated Biotinylated Kinases
Carna Biosciences Technical Note No. 1
-
Newsletter
Targeted Degradation of Non-catalytic Kinases New Drug Discovery Options
Carna Biosciences Newsletter Vol. 10
-
Newsletter
Drug-resistant EGFR mutations in lung cancer
Carna Biosciences Newsletter Vol. 9
-
Newsletter
Kinetic analysis of covalent and irreversible inhibitors
Carna Biosciences Newsletter Vol. 8
-
Technical Note
The importance of assessing intrinsic target kinase activity
Carna Biosciences Technical Note No. 2
-
Technical Note
Production of Highly Active Protein Kinases for Drug Discovery Applications
Carna Biosciences Technical Note No. 1
-
Newsletter
Kinase Inhibitors in the Fight against COVID-19
Carna Biosciences Newsletter Vol. 7
-
Newsletter
Recommendations for off-target profiling
Carna Biosciences Newsletter Vol. 6
-
Newsletter
The significance of ATP concentration in cell-free and cell-based assays
Carna Biosciences Newsletter Vol. 4
-
Newsletter
Targeted Protein Degraders
Carna Biosciences Newsletter Vol. 3
-
Newsletter
Residence time and compound selectivity
Carna Biosciences Newsletter Vol. 2
-
Newsletter
A story about biotin-avidin affinity and how it accelerates small molecule drug discovery
Carna Biosciences Newsletter Vol. 1